Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition

Innovative strategies are necessary to maximize the clinical application of HIV neutralizing antibodies. To this end, bispecific constructs of human antibody F240, reactive with well-conserved gp41 epitope and antibody 14A8, reactive with the IgA receptor (CD89) on effector cells, were constructed....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaocong, Duval, Mark, Gawron, Melissa, Posner, Marshall R., Cavacini, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933884/
https://www.ncbi.nlm.nih.gov/pubmed/27419146
http://dx.doi.org/10.1155/2016/9425172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933884/
https://www.ncbi.nlm.nih.gov/pubmed/27419146
http://dx.doi.org/10.1155/2016/9425172

Ejemplares similares